Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894882 | 0.84 | TSHR (0.46) | ESR1NR3C2MEN1KMT2AHPGD | |
| SCHEMBL11123788 | 0.82 | L3MBTL1 (0.46) | PKMNR3C2MEN1HTTKMT2A | |
| SCHEMBL28296744 | 0.81 | PKM (0.37) | PKMESR1NR3C2CA12CA9 | |
| SCHEMBL129629 | 0.80 | PKM (0.56) | PKMESR1NR3C2MEN1HTT | |
| SCHEMBL5720785 | 0.80 | ALDH1A1 (0.47) | ESR1KMT2ACA12CA9CA2 | |
| SCHEMBL9051259 | 0.80 | L3MBTL1 (0.47) | ALDH1A1 | |
| SCHEMBL27792301 | 0.80 | PKM (0.39) | PKMESR1NR3C2KMT2ACA12 | |
| SCHEMBL2513199 | 0.79 | NR3C2 (0.44) | PKMESR1NR3C2MEN1HTT | |
| SCHEMBL171307 | 0.77 | ALDH1A1 (0.54) | NR3C2MEN1HTTKMT2ACA12 | |
| SCHEMBL894821 | 0.77 | KMT2A (0.44) | ESR1KMT2ACA12CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113200891-B | Preparation method of cis-N-styryl amide derivative | 华侨大学 | 2022-09-30 | — | — | CN | disclosed |
| US-8487094-B2 | Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| CN-101679363-B | Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same | KOWA CO | 2013-06-05 | — | — | CN | disclosed |
| US-8329897-B2 | Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2183229-B1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20110269957-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| CN-102105454-A | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 | BOEHRINGER INGELHEIM INT | 2011-06-22 | — | — | CN | disclosed |
| EP-2323994-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2183229-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| CN-101679363-A | Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| WO-2010010150-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009017671-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20070088142-A1 | PERFLUOROVINYL ETHER MONOMER HAVING A SULFONAMIDO GROUP | IKEDA MASANORI | 2007-04-19 | — | — | US | disclosed |
| EP-0664321-B1 | Polycarbonates stabilized against radiation | BAYER AG (DE) | 2003-04-16 | — | — | EP | disclosed |
| US-5612398-A | Radiation-resistant polycarbonates | BAYER AG (DE) | 1997-03-18 | — | — | US | disclosed |
| EP-0664321-A1 | Polycarbonates stabilized against radiation | BAYER AG (DE) | 1995-07-26 | — | — | EP | disclosed |
| CN-1040594-A | The method for making of neuropeptide tyrosine antagonist | MERRELL DOW PHARMA (US) | 1990-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269957-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | PKM 1495/4885ESR1 2071/4885NR3C2 32/4885 |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD11B2, HSD17B1 | PKM 1326/4885ESR1 2186/4885NR3C2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.